A study of the effect of administering Nivolumab with a CCR2/5-inhibitor or anti-IL8 (BMS-986253) before or after surgery is undergoing evaluation as a means of improving survival in HCC patients (NCT04123379). This evidence concerns the gene CCR2 and hepatocellular carcinoma.